| Literature DB >> 25954256 |
Marie Beaume1, Thilo Köhler1, Thierry Fontana1, Mikael Tognon1, Adriana Renzoni2, Christian van Delden1.
Abstract
BACKGROUND: Chronic airway infection by Pseudomonas aeruginosa considerably contributes to lung tissue destruction and impairment of pulmonary function in cystic-fibrosis (CF) patients. Complex interplays between P. aeruginosa and other co-colonizing pathogens including Staphylococcus aureus, Burkholderia sp., and Klebsiella pneumoniae may be crucial for pathogenesis and disease progression.Entities:
Keywords: Pseudomonas aeruginosa; Staphylococcus aureus; beneficial interactions; direct competition; exploitative competition; respiratory pathogens
Year: 2015 PMID: 25954256 PMCID: PMC4407587 DOI: 10.3389/fmicb.2015.00321
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Plasmids and strains.
| Plasmids or strains | Description | Reference |
| pIApX2 | Broad-host-range cloning vector, pUCP20 derivative | I. Attree (Grenoble, France; |
| pME3087 | Mobilizable suicide vector, ColE1 | |
| pMMB207 | Expression plasmid with inducible tac/lacUV5 promoter | |
| pPqsCDE | This study | |
| pCarB | This study | |
| pBioA | This study | |
| pPurF | This study | |
| PA14 | Clinical isolate UCBPP-PA14 | |
| PA14 | Transposon inserted into the | This study |
| PA14 | Transposon inserted into the | This study |
| PA14 | Transposon inserted into the | This study |
| PA14 | Transposon inserted into the | This study |
| PA14 | This study | |
| PA14 | This study | |
| PA14 | This study | |
| PA14 | This study | |
| PA14 | This study | |
| PA14 | This study | |
| PA14 | This study | |
| PA14 | This study | |
| PA14 Δ | This study | |
| PAO1 Δ | ||
| PA14 | Mutated PA14 strain containing a nonsense point mutation in | |
| PA14 | Mutated PA14 strain containing a non-polar deletion of | |
| PA14 | Mutated PA14 strain containing a | |
| PA14 | Isogenic non-polar | |
| RP4-2-Tc::Mu | ||
| Clinical strain, MRSA | ||
| Clinical strain | University Hospitals of Geneva | |
| Non-capsulated | Laboratory collection | |
| Clinical strain from CF-patient | This study | |
| Clinical strain from CF-patient | This study |
Primers used in this study
| Primers | Amplified gene(s) | Sequences (5′–3′) | Final concentration (μM) |
| ARB1 | GGCCACGCGTCGACTAGTACNNNNNNNNNNGATAT | 0.5 | |
| ARB2 | GGCCACGCGTCGACTAGTAC | 0.4 | |
| MCL195 | GATCCCGCAGTGGCTCTCTATACAAAGTTG | 0.2 | |
| MCL210 | TGGTGCTGACCCCGGATGAAG | 0.4 | |
| PurF-Kpn | ACA | 0.6 | |
| PurF-BamHI | ACA | 0.6 | |
| BioA-Kpn | ACAGGTACCTGAACACCCCCAACATGAGA | 0.6 | |
| BioA-R_BamHI | ACA | 0.6 | |
| CarB-F_BamHI | ACA | 0.6 | |
| CarB-R_HindIII | ACA | 0.6 | |
| pqsC-Xba | ACAC | 0.6 | |
| pqsC-Hind | ACAC | 0.6 | |
| LasAF-Eco | 5′
| CCCG | 0.6 |
| LasAR-Bam | CCGC | 0.6 | |
| LasAF-Bam | 3′
| CCGC | 0.6 |
| LasAR-Hind | CCCC | 0.6 |